Mike Hollan

Krieger Scientific's Joseph Morwald on why unverified AI-generated documentation in pharma is a complex issue with potentially significant consequences.

Krieger Scientific's Joseph Morwald explains how siloed departments, disconnected systems, and a lack of cross-functional accountability are creating the structural compliance gaps that FDA warning letters keep exposing.

Krieger Scientific's Joseph Morwald on why over-reliance on AI and under-reliance on human expertise is driving the surge in FDA warning letters.

Incubate’s executive director discusses China’s rise in biotech and why the US’ best response may be to focus on its own issues.

AstraZeneca and BMS held merger talks, Incubate's John Stanford on fixing the US pharma ecosystem, and why real-time clinical trial data matters.

Incubate’s executive director discusses China’s rise in biotech and why the US’ best response may be to focus on its own issues.

John Stanford, executive director at Incubate, explains the COINS Act debate: should Treasury restrict US biotech investment in China, and what happens to American leadership if it does.

Incubate’s executive director John Stanford defines the three buckets of the US-China pharma challenge: API manufacturing, clinical trial competitiveness, and the complex ethics of licensing Chinese innovation.

LucyRx’s chief commercial officer explains why the traditional two-bucket approach to GLP-1 coverage, which focuses on diabetes and weight loss, leaves high-risk populations without access.

John Stanford, executive director at Incubate, discusses how China's two decades of biotech investment are paying off.

TruTechnologies chairman and co-founder argues that while Operation TrialBlazer is directionally correct in targeting regulatory friction, it misses the larger problem.

TruTechnologies’ Dr. Richard Graham explains where he sees the actual issues that need to be addressed at FDA.

Susan Thomas, chief commercial officer at LucyRx, discusses how women in a certain age range are disproportionately impacted by cardiovascular risk.

Dr. Stoehr, neuroscience researcher at AbbVie discusses how biomarkers are opening a new window into Parkinson’s disease.

Chief commercial officer Susan Thomas from LucyRx explains why coverage isn’t a one-size-fits all problem.

Dr. Richard Graham, chairman and co-founder of TruTechnologies, discusses the importance of global clinical trials while also being a center for these trials.

TruTechnologies’ chairman and co-founder Dr. Richard Graham explains why Australia and China are the main competitors for clinical trials.

LucyRx’s chief commercial officer Susan Thomas discusses the impact that only looking at immediate cost impact has on certain indications.

Dr. Richard Graham from TruTechnologies details the likelihood that Project Trialblazer reduces trial times by 6-to-12 months.

Susan Thomas, chief commercial officer at LucyRx, explains the areas where GLP-1 coverage still lacks.

Nuvation Bio’s president, CEO, and founder discusses the company’s mission, approach to developing a global strategy, and how it manages its increasing pipeline.

Nuvation CEO David Hung discusses his leadership style, success stories for building camaraderie, and his inspiration for joining the pharma and biotech industry.

David Hung, CEO of Nuvation Bio, details the company’s ongoing trials for new drugs and new indications for existing molecules.

Nuvation’s CEO David Hung details the various cancer medications the company has on the market and in clinical trials.

David Hung, CEO of Nuvation Bio, explains the company’s current focus on US operations and how it utilizes partners for global impact.

Nuvation Bio’s CEO David Hung discusses the how Nuvation built a relatiohsip with Daichii Sankyo.

RedSail Technologies’ vp of clinical services discusses awareness and education gaps in how patients understand GLP-1s.

David Hung, Nuvation Bio’s CEO, explains the company’s focus on providing patients with better drugs.

In today's Pharmaceutical Executive Daily, Novartis files notices to lay off 322 employees at its East Hanover, New Jersey location, Evogene partners with Tel Aviv University's Blavatnik Center for Drug Discovery to accelerate AI-powered small-molecule discovery, and Sanofi's Chief Digital Officer Emmanuel Frenehard on why genuine AI transformation requires concentrated investment—not just automation.

The two companies will work together to advance the development of small molecule discovery at the research center.